@article{4290949cce364092a5505d7ed3a17ecd,
title = "Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis",
abstract = "Brensocatib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit-risk profile. https://bit.ly/3SbisW3.",
author = "Chalmers, {James D.} and Metersky, {Mark L.} and Joseph Feliciano and Carlos Fernandez and Ariel Teper and Andrea Maes and Mariam Hassan and Anjan Chatterjee",
note = "Funding Information: This study was funded by Insmed Incorporated. Copyright: {\textcopyright} The authors 2023.",
year = "2023",
month = may,
day = "1",
doi = "10.1183/23120541.00695-2022",
language = "English",
volume = "9",
journal = "ERJ Open Research",
issn = "2312-0541",
publisher = "European Respiratory Society",
number = "3",
}